Moderate Plaque psoriasis
Drug | Drug Name | Drug Description |
---|---|---|
DB12917 | Bimekizumab | An anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis. |
DB11776 | Brodalumab | A monoclonal antibody used to treat moderate to severe plaque psoriasis. |
DB01013 | Clobetasol propionate | A corticosteroid used to treat corticosteroid-responsive dermatoses and plaque psoriasis. |
DB16650 | Deucravacitinib | A TYK2 inhibitor being investigated as a treatment for psoriasis. |
DB00005 | Etanercept | A protein therapy based on the binding fragment of the tumour necrosis factor alpha receptor used to treat severe rheumatoid arthritis and moderate to severe plaque psoriasis. |
DB11834 | Guselkumab | A monoclonal antibody used to treat moderate to severe plaque psoriasis. |
DB09029 | Secukinumab | An immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders. |
DB05679 | Ustekinumab | A targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis. |
Drug | Drug Name | Phase | Status | Count |
---|---|---|---|---|
DB11834 | Guselkumab | 3 | Active Not Recruiting | 1 |
DB16650 | Deucravacitinib | 4 | Recruiting | 1 |
DB14762 | Risankizumab | 4 | Recruiting | 1 |